Kaposi’s Sarcoma (KS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Kaposi’s sarcoma (KS) is a malignant neoplasm of the vascular endothelium that is multifocal, involving the skin and other organs. Based on epidemiological features, four types of Kaposi’s sarcoma have been recognised: classic, endemic, iatrogenic and epidemic (AIDS related). The course of KS ranges from indolent, with only skin manifestations, to fulminant, with extensive visceral involvement. Because of its broad morphologic spectrum and similarities to many benign vasoproliferative lesions (e.g., microvenular hemangioma, bacillary angiomatosis, and pyogenic granuloma) and tumors with a prominent spindle cell component, KS poses difficulties in histologic diagnosis. The variability in the behavior of KS among individuals in the same group remains enigmatic. Clinically, Kaposi sarcoma is a vascular lesion that frequently manifests as a violaceous pink to the purple plaque on the skin or mucocutaneous surfaces. Lesions can be painful, especially if they are associated with lymphedema and secondary infection. The skin has three primary stages: patch, plaque, and nodule. Lesions may ulcerate or invade nearby tissues. In addition to involving lymph nodes, KS has a predilection for the lungs and gastrointestinal system but can also occur in other visceral organs. Respiratory involvement has been linked to death from Kaposi sarcoma.
·
The incidence of Kaposi’s sarcoma (KS) ranges
from 1 to 1.5 cases per 100,000 population in the USA.
Thelansis’s “Kaposi’s Sarcoma (KS)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Kaposi’s
Sarcoma (KS) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Kaposi’s Sarcoma (KS) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Kaposi’s Sarcoma (KS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment